Fennec Pharmaceuticals: A Compelling Single-Asset Growth Story For 2026

Company Overview - Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on producing a drug aimed at reducing cisplatin-induced ototoxicity (CIO) [1] - The drug is marketed as Pedmark in the US and Pedmarqsi in Europe, which is a sodium thiosulfate injection [1] Product Details - Cisplatin is recognized as a highly effective chemotherapy agent, but it is associated with significant side effects, including ototoxicity [1]